SYPL2 (synaptophysin-like 2, also known as MG29) encodes a membrane protein related to synaptophysin, a major constituent of synaptic vesicles. In the context of metabolism, SYPL2 is expressed in adipose tissue and skeletal muscle and appears to influence fat cell biology and the response to physical activity. The rs62623713 variant introduces a missense substitution — glutamic acid to glycine at position 99 (E99G) — in a protein already implicated in adipose function by animal studies showing that mice lacking Sypl2 display reduced body weight¹¹ mice lacking Sypl2 display reduced body weight
Jiao et al., European Journal of Human Genetics, 2015.

The G allele is rare globally (approximately 4–6% in Europeans, under 0.1% in East Asians), placing this variant in the category of low-frequency coding variants rather than common GWAS polymorphisms. Its rarity made it invisible to early GWAS arrays, requiring exome sequencing to discover — a study design that is increasingly revealing low-frequency variants with larger per-allele effect sizes than common SNPs.

The Mechanism

The E99G substitution replaces a charged glutamic acid with the smallest amino acid, glycine, at position 99 of the SYPL2 protein. This change occurs in the cytoplasmic domain of the protein, potentially altering its interaction with intracellular partners involved in vesicular trafficking and membrane dynamics. Although computational predictions (SIFT score 0.58, PolyPhen score 0.0) classify the substitution as "tolerated" and "benign," these scores reflect evolutionary conservation rather than quantitative metabolic effects, and the observed human phenotype suggests functionally relevant consequences in adipose tissue not captured by these algorithms.

SYPL2 expression is notably down-regulated in less physically active children²² down-regulated in less physically active children
Galmés et al., Scientific Reports, 2023, alongside other genes associated with cardiometabolic benefit. This positions SYPL2 at the intersection of physical activity response and metabolic phenotype, though the precise molecular pathway linking E99G to increased adiposity remains to be fully characterized.

The Evidence

The primary discovery came from a 2015 exome sequencing study³³ 2015 exome sequencing study
Jiao H et al., European Journal of Human Genetics by researchers at Karolinska Institutet. Using pooled exome sequencing in 100 morbidly obese and 100 normal-weight Swedish subjects, followed by validation in 3,197 genotyped individuals, they identified rs62623713 as a low-frequency (minor allele frequency 2.9%) non-synonymous variant with striking effect size: each G allele increased BMI by 2.13 kg/m² (95% CI: 1.09–3.18, p = 6.28 × 10⁻⁵) and conferred an odds ratio of 1.32 for morbid obesity. This effect size is notably larger than common obesity variants⁴⁴ notably larger than common obesity variants
Common GWAS hits like FTO rs9939609 increase BMI by only ~0.4 kg/m² per allele, consistent with the general observation that rare coding variants carry larger per-allele effects.

A 2016 follow-up study⁵⁵ 2016 follow-up study
de Toro-Martín J et al., Obesity Science & Practice from Laval University extended the analysis to 3,693 participants from two Canadian cohorts, genotyping rs62623713 alongside two additional SYPL2 tagging SNPs (rs9661614 and rs485660). This study revealed a notable sex-specific dimension: tagging SNPs in the SYPL2 region associated with hip circumference specifically in women (FDR-corrected p = 1.7 × 10⁻²), suggesting that SYPL2 may preferentially influence a gynoid (hip-and-thigh) pattern of fat deposition in females. Male participants showed no significant associations with hip circumference, pointing to sex-hormone modulation of SYPL2's role in regional adipose distribution.

Critically, the evidence requires context: both studies used relatively modest sample sizes by modern GWAS standards, and the Jiao 2015 discovery cohort was a Swedish population, raising questions about generalizability. The variant has not yet been independently replicated in large-scale exome sequencing studies, and it does not appear in the NHGRI-EBI GWAS Catalog of genome-wide significant findings. The evidence level is therefore classified as emerging — a biologically plausible association with suggestive statistics, but requiring replication in larger, diverse cohorts before clinical utility can be established.

Practical Actions

For carriers of the G allele, the actionable message centers on lifestyle factors that are particularly relevant given the metabolic phenotype associated with SYPL2. Physical activity data specifically show SYPL2 expression is coupled to active status, suggesting that movement may partially compensate for the functional effects of the E99G variant. Women carrying G alleles who are concerned about gynoid fat distribution have additional context from the de Toro-Martín follow-up.

Given the emerging evidence status, specific dietary or supplementation protocols targeting SYPL2 biology are not yet established. The primary practical value of this variant lies in its contribution to personalized obesity risk assessment and motivating attention to body composition monitoring and physical activity behaviors that evidence links to SYPL2 expression.

Interactions

SYPL2's role in fat distribution shows sex-specific patterns, with the strongest associations in women for hip circumference. This suggests potential interaction with sex hormone signaling pathways in adipose tissue. The de Toro-Martín study found that tagging SNPs rs9661614 and rs485660 recapitulate much of the regional distribution phenotype, indicating these variants likely tag the same functional haplotype as rs62623713.

No documented compound interactions with other obesity-related variants (such as FTO rs9939609 or MC4R variants) have been studied for rs62623713, though pathway-level interactions in adipose biology are biologically plausible. Given the similar biological domain — adipose tissue and body composition — future studies may find additive effects with more common obesity variants.

The BCO1 gene encodes beta-carotene 15,15'-monooxygenase¹¹ beta-carotene 15,15'-monooxygenase
The enzyme that symmetrically cleaves one molecule of beta-carotene into two molecules of retinal, which is then reduced to retinol — the form of vitamin A used by the body, the key enzyme converting plant-based provitamin A into biologically active vitamin A. Most genetic studies of BCO1 focus on two coding variants — rs7501331 (Ala379Val) and rs12934922 (Arg267Ser) — that directly alter the enzyme's amino acid sequence. The rs6564851 variant operates at a different level entirely: located approximately 7.6 kb upstream of the BCO1 coding sequence, it is a regulatory SNP²² regulatory SNP
A non-coding variant that modifies gene expression or enzyme activity through changes to transcription factor binding sites, promoter elements, or chromatin accessibility rather than altering the protein sequence itself that emerged as the top genome-wide association signal for circulating beta-carotene levels across three independent cohorts.

The Mechanism

rs6564851 sits in an intergenic region at chromosome 16q23.2 (GRCh38 position 81,230,991), roughly 7.6 kb upstream from the BCO1 transcription start site — a location consistent with enhancer or promoter-proximal elements³³ enhancer or promoter-proximal elements
Regulatory DNA that can influence the transcription rate of a nearby gene; such elements often contain binding sites for transcription factors that activate or repress gene expression in a tissue-specific manner. The G allele is associated with reduced BCO1 enzyme activity. In a controlled pharmacokinetic study by Lietz et al. 2012⁴⁴ Lietz et al. 2012
Lietz G et al. Single nucleotide polymorphisms upstream from the β-carotene 15,15'-monoxygenase gene influence provitamin A conversion efficiency in female volunteers. J Nutr, 2012, the rs6564851 G allele was associated with a 48% reduction in BCMO1 catalytic activity in female volunteers. Carriers of the T allele (the better-converting allele) showed a positive correlation with the retinyl palmitate-to-beta-carotene ratio after a pharmacological beta-carotene dose (r = 0.41; P = 0.028), confirming that this upstream variant independently modulates the efficiency of the conversion step.

The net effect is a paradox that is characteristic of poor BCO1 converter status: because less beta-carotene is being cleaved, circulating beta-carotene levels rise while retinol production from plant sources falls. This is precisely what the GWAS data show — Ferrucci et al. 2009⁵⁵ Ferrucci et al. 2009
Ferrucci L et al. Common variation in the beta-carotene 15,15'-monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study. Am J Hum Genet, 2009 found that each G allele is associated with a 0.27 standard deviation increase in plasma beta-carotene (p = 1.6 × 10⁻²⁴), while also reducing circulating lycopene, zeaxanthin, and lutein — a multi-carotenoid signature consistent with reduced cleavage activity across the entire carotenoid pathway.

BCO1 also possesses eccentric cleavage activity⁶⁶ eccentric cleavage activity
Asymmetric cleavage of carotenoids at positions other than 15,15', producing apo-carotenals and other bioactive metabolites including lycopene and lutein cleavage products; this secondary activity may explain why BCO1 variants affect non-beta-carotene carotenoids toward lycopene and other non-provitamin-A carotenoids, which explains the broader carotenoid profile changes seen with this variant beyond beta-carotene alone.

The Evidence

The founding association evidence comes from a multi-cohort GWAS by Ferrucci et al. 2009⁷⁷ Ferrucci et al. 2009
Ferrucci L et al. Common variation in the beta-carotene 15,15'-monooxygenase 1 gene affects circulating levels of carotenoids. Am J Hum Genet, 2009 in 3,941 participants across three studies (InCHIANTI, Women's Health and Aging Study, ATBC). The association with beta-carotene reached p = 1.6 × 10⁻²⁴ with effect sizes of 0.10–0.28 SDs per allele across multiple carotenoids. Importantly, plasma retinol itself showed no significant association — consistent with BCO1 impairment being compensated in people with mixed diets who obtain retinol directly from animal foods.

Mechanistic confirmation came from Lietz et al. 2012, who measured actual enzyme kinetics and pharmacokinetic responses in a controlled feeding study of female volunteers. The study was conducted exclusively in women — the functional activity reduction of 48% cannot be assumed to apply equally to males based on current data. Two nearby upstream variants (rs6420424, −59% activity; rs11645428, −51% activity) showed even larger effects, and all three variants together define a regulatory haplotype that substantially modulates BCO1 output independently of the coding variants.

The causal, not merely associative, nature of the rs6564851 effect on carotenoid metabolism was confirmed by a Mendelian randomization study by Perry et al. 2009⁸⁸ Perry et al. 2009
Perry JR et al. Circulating beta-carotene levels and type 2 diabetes — cause or effect? Diabetologia, 2009: the G allele raises circulating beta-carotene by 0.27 SD per allele as an instrumental variable, yet shows no association with type 2 diabetes (OR 0.98, 95% CI 0.93–1.04), confirming that the beta-carotene elevation reflects accumulation from reduced conversion, not higher dietary intake.

A small study by Feigl et al. 2014⁹⁹ Feigl et al. 2014
Feigl B et al. The relationship between BCMO1 gene variants and macular pigment optical density in persons with and without AMD. PLoS One, 2014 in 44 participants found that TT homozygotes had significantly higher macular pigment optical density than GG homozygotes (p < 0.01), consistent with the T allele facilitating better conversion and delivery of lutein and zeaxanthin to the macula. This effect was absent in AMD patients, possibly due to disease-related disruption of macular carotenoid transport.

Practical Implications

The central practical consequence is for people who rely on plant-based provitamin A. Dietary vitamin A comes in two forms: preformed retinol¹⁰¹⁰ preformed retinol
Found in animal products — liver, egg yolks, dairy, fatty fish — and absorbed directly without needing the BCO1 enzyme. The most reliable source for people with impaired beta-carotene conversion from animal sources and provitamin A carotenoids (primarily beta-carotene) from plants. G allele carriers convert less of their dietary beta-carotene to retinol; for omnivores, this is largely inconsequential because animal-source retinol bypasses BCO1 entirely. For vegans and vegetarians who rely exclusively on plant carotenoids for vitamin A, GG homozygosity represents a meaningful barrier to meeting vitamin A needs from diet alone.

The G allele is strikingly common in East Asian populations (~82% allele frequency), compared to ~51% in European and ~39% in African populations. This population difference is relevant in regions where plant-based diets are traditional — high G allele prevalence alongside plant-dominant diets may contribute to population-level vitamin A insufficiency patterns.

Macular health is a secondary concern: reduced BCO1 activity from the G allele may also lower the delivery of lutein and zeaxanthin to the retina, both of which are concentrated in the macula¹¹¹¹ macula
The central region of the retina responsible for sharp, detailed vision; its yellow pigmentation comes from concentrated lutein and zeaxanthin, which filter blue light and act as local antioxidants and protective against age-related macular degeneration.

Interactions

rs6564851 is on chromosome 16 (position 81,230,991), co-located with the BCO1 coding variants rs7501331 (Ala379Val) and rs12934922 (Arg267Ser). Although all three variants are in the BCO1 locus, the upstream regulatory variant and the coding variants represent distinct mechanisms — regulatory effects on expression versus structural effects on enzyme activity — and are expected to exert additive impairment when present together. Individuals carrying G alleles at rs6564851 alongside T alleles at rs7501331 and/or minor alleles at rs12934922 face cumulative BCO1 dysfunction combining both reduced enzyme quantity and reduced enzyme quality.

rs7834555, the other BCO1-related variant in the GeneOps database, is located on chromosome 8 (position 81,785,389) — a completely different chromosome from rs6564851. They are by definition not in linkage disequilibrium and represent fully independent genetic influences on carotenoid metabolism, likely through different biological mechanisms.

The broader regulatory haplotype at the rs6564851 locus includes rs6420424 and rs11645428, both of which show even larger activity reductions (59% and 51%, respectively) in the Lietz 2012 study. These three upstream variants likely tag the same or overlapping regulatory region and may be partially in LD with each other.

Sarcoidosis is a mysterious inflammatory disease in which the immune system forms granulomas¹¹ granulomas
Compact clusters of activated macrophages and lymphocytes that represent a failed attempt to wall off a perceived pathogen; in sarcoidosis no infectious agent is consistently found in the lungs and other organs. It strikes disproportionately in people of African descent and in Scandinavians, peaks between ages 25–45, and ranges from self-resolving (Löfgren's syndrome) to chronic and progressive lung disease. The gene ANXA11 — encoding annexin A11, a calcium-dependent membrane-binding protein — lies on chromosome 10q22.3, and rs7091565 sits in its 3' untranslated region, tagging a haplotype that alters sarcoidosis susceptibility by roughly 30–50%.

The Mechanism

Annexin A11 is a 56-kDa protein in the annexin superfamily, characterized by conserved C-terminal repeats that bind calcium and phospholipid membranes²² repeats that bind calcium and phospholipid membranes
These repeats are shared across all 12 human annexins; the unique N-terminal domain of ANXA11 is the region most divergent between family members and the functional hotspot for genetic variants. It is expressed broadly across tissues, with particularly high levels in the esophagus, heart, and lung. Its roles include regulating apoptosis (programmed cell death), cytokinesis, phagocytosis, and calcium-dependent signaling in immune cells — all processes central to the macrophage hyperactivation that characterizes sarcoidosis.

The functional missense variant rs1049550 (ANXA11 R230C) lies 13 kb downstream of rs7091565 within the same gene. This substitution — arginine to cysteine at position 230 of the protein — falls in the N-terminal regulatory domain and alters the protein's ability to interact with binding partners involved in apoptosis regulation. Importantly, rs7091565 and rs1049550 are in strong linkage disequilibrium³³ strong linkage disequilibrium
LD means the two alleles are inherited together on the same chromosome segment far more often than chance; carriers of one allele almost always carry the paired allele at the other site: the C allele at rs7091565 co-segregates with the C allele at rs1049550 (the arginine/risk haplotype), while the T allele at rs7091565 co-segregates with the T allele at rs1049550 (the cysteine/protective haplotype). This LD relationship makes rs7091565 a proxy marker for the functional R230C variant.

The mRNA expression of ANXA11 is not altered⁴⁴ mRNA expression of ANXA11 is not altered
This rules out differential transcription as the explanation; the R230C variant changes protein structure and apoptotic function, not expression level by rs1049550 genotype. Instead, the R230C substitution appears to modulate ANXA11's apoptotic activity directly: the arginine-230 (C allele) form is associated with impaired granuloma resolution, while the cysteine-230 (T allele) form may alter calcium-dependent interactions that improve macrophage death signaling and granuloma clearance.

The Evidence

rs7091565 was identified in the first genome-wide association study of sarcoidosis⁵⁵ first genome-wide association study of sarcoidosis
A GWAS scans ~440,000–1,000,000 common variants across the genome simultaneously, identifying statistical associations without assuming a biological hypothesis in advance by Hofmann et al. (Nature Genetics, 2008). In 499 German cases and 490 controls with validation in 1,649 cases and 1,832 controls, rs7091565 reached p = 1.0×10⁻⁵ in the validation cohort. The lead signal at the ANXA11 locus was rs2789679 (p = 3.0×10⁻¹³), with rs7091565 and the functional R230C variant (rs1049550) in its LD block.

The protective T allele has since been confirmed across multiple independent cohorts. A functional study⁶⁶ functional study
245 Czech sarcoidosis patients and 254 healthy controls; mechanistic cell biology experiments by Mrazek et al. (Genes & Immunity, 2011) found the T allele significantly less frequent in sarcoidosis cases (35%) versus controls (42%, OR 0.77, p=0.04). The T allele was particularly depleted in patients with pulmonary parenchymal infiltration compared to isolated hilar lymphadenopathy — suggesting it modifies not just susceptibility but disease severity.

The most comprehensive evidence comes from a meta-analysis⁷⁷ meta-analysis
Pooling data from 6 cohorts including European, African American, and Asian populations by Karakaya et al. (Cells, 2022): T allele protective in both Löfgren's syndrome (OR 0.69, 95% CI 0.52–0.92, p=0.01) and chronic sarcoidosis (OR 0.51, 95% CI 0.36–0.70, p=4×10⁻⁵), with a pooled OR of 0.70 (95% CI 0.66–0.75, p = 3.58×10⁻²⁹) — a highly significant and consistent protective signal. A separate multi-ethnic replication⁸⁸ multi-ethnic replication
1,689 cases and 1,252 controls in African Americans and European Americans by Levin et al. identified additional ANXA11 variants in African Americans and a significant interaction between rs1049550 and the HLA-DRA locus, pointing to a joint ANXA11–HLA axis in sarcoidosis immunopathology.

Practical Actions

The T allele at rs7091565 is substantially protective against sarcoidosis (approximately 30–50% reduced odds), while CC homozygotes carrying no protective T alleles have the highest risk at this locus. Sarcoidosis most commonly presents with dry cough, shortness of breath, fatigue, and bilateral hilar lymphadenopathy on chest X-ray. Skin involvement (erythema nodosum, lupus pernio), eye inflammation (uveitis), and cardiac arrhythmia are extrapulmonary manifestations.

For C-allele carriers, the most clinically actionable step is awareness: unexplained dry cough lasting more than 8 weeks, eye inflammation, or skin nodules warrant chest imaging, as sarcoidosis is often under-recognized in primary care. Pulmonary function testing and bronchoalveolar lavage can confirm diagnosis. Most cases are self-limited and require only monitoring; severe or progressive disease is treated with corticosteroids.

There is no dietary intervention proven to modify ANXA11-mediated sarcoidosis risk, but the inflammatory granuloma pathology can impair vitamin D metabolism — granuloma macrophages convert 25(OH)D to the active 1,25(OH)₂D form autonomously, leading to hypercalcemia in some patients. This makes calcium-containing supplements potentially contraindicated in active sarcoidosis, unlike most other inflammatory conditions.

Interactions

rs7091565 acts as a proxy for the functional rs1049550 R230C variant, so the two should not be treated as independent signals — they capture the same underlying biological effect. The sarcoidosis-risk haplotype at ANXA11 also includes rs2789679 (the lead GWAS SNP), rs2573346, and rs1953600, all in strong LD.

The interaction with HLA-DRA (rs9268839) is noteworthy: Levin et al. found a significant SNP-SNP interaction between rs1049550 and this HLA locus in African Americans, suggesting that ANXA11 risk is potentiated when combined with certain MHC class II alleles that drive the antigen-presentation arm of granuloma formation. This is biologically coherent — ANXA11 influences the apoptotic fate of macrophages forming the granuloma, while HLA-DRA governs the T-cell activation that recruits them. Risk at both loci simultaneously would amplify the inflammatory cascade from two independent points.

PTPN22 rs2476601 (R620W) is a broad autoimmune susceptibility variant that, while not studied specifically with ANXA11 in sarcoidosis, modulates T-cell receptor signaling and could compound ANXA11-mediated macrophage dysregulation in susceptible individuals.

Obscurin is one of the largest proteins in the human body — a giant cytoskeletal scaffold encoded by the OBSCN gene on chromosome 1q42. In cardiac and skeletal muscle, obscurin anchors the sarcoplasmic reticulum to the sarcomere¹¹ obscurin anchors the sarcoplasmic reticulum to the sarcomere
The protein integrates structural and signalling functions at the M-band of the sarcomere, coordinates myofibrillogenesis, and regulates calcium cycling during contraction and relaxation. The rs71180793 variant is a single-nucleotide deletion (c.23838del) that shifts the reading frame in the OBSCN coding sequence, creating a premature stop and truncating the obscurin protein at around serine-7947 (isoform C numbering). Whether this frameshift is sufficient alone to cause cardiomyopathy remains contested — ClinVar records conflicting interpretations ranging from benign to uncertain significance — but a growing body of evidence links OBSCN protein-truncating variants as a class to cardiomyopathy risk, particularly in adults.

The Mechanism

The rs71180793 deletion removes one cytosine from a homopolymeric CCCCC run in exon coding sequence, causing a frameshift at p.Ser7947²² frameshift at p.Ser7947
The exact amino acid position varies by isoform; p.Ser6990fs in isoform b. The truncated protein loses obscurin's C-terminal kinase domains and the titin-binding SK3 domain, which are critical for sarcoplasmic reticulum organization and RhoGEF signalling. Mechanistically, the likely disease model is haploinsufficiency³³ haploinsufficiency
One functional copy produces insufficient obscurin protein to maintain normal sarcomere architecture: truncating mutations reduce total obscurin immunoreactive material to 45–72% of normal in explanted DCM hearts. This partial depletion may disrupt SR anchorage and calcium handling, increasing arrhythmia susceptibility. Murine obscurin-knockout models confirm the downstream consequences: hearts lacking obscurin show larger ventricular volumes, reduced fractional shortening, impaired beta-adrenergic response, and increased ventricular tachycardia inducibility⁴⁴ hearts lacking obscurin show larger ventricular volumes, reduced fractional shortening, impaired beta-adrenergic response, and increased ventricular tachycardia inducibility
Knockout model; end-diastolic volume increased 20%.

The Evidence

Evidence for OBSCN truncating variants as a cardiac risk class is accumulating, though the evidence for rs71180793 specifically remains emerging. In the largest study to date, Wu et al. 2021 performed whole-exome sequencing on 986 HCM patients and 761 controls⁵⁵ Wu et al. 2021 performed whole-exome sequencing on 986 HCM patients and 761 controls
Replication cohort: 529 HCM patients and 307 controls; combined OR 3.58 and identified 28 qualifying OBSCN truncating variants in 2.6% of HCM patients versus 0.8% of controls (combined OR 3.58, p<0.001). Carriers had significantly worse outcomes over a mean 3.3-year follow-up: adjusted HR 3.1 (95% CI 1.40–6.70) for cardiovascular death and 2.63 (95% CI 1.21–5.71) for all-cause mortality. A separate proteomic study of explanted DCM hearts⁶⁶ explanted DCM hearts
30 patients with familial DCM; whole-exon sequencing of 58 disease genes identified five OBSCN mutations in four samples, with haploinsufficient protein expression in all three assayed samples. The Genomics England cohort analysis⁷⁷ Genomics England cohort analysis
926 adult cardiomyopathy patients independently confirmed that OBSCN was among the top mutated genes in adult DCM, enriched for protein-truncating variants.

The picture is more nuanced for rs71180793 itself. ClinVar lists three submissions with conflicting results: one benign call (Labcorp Genetics), one uncertain significance (Greenwood Genetic Center), and one likely benign (CeGaT). A separate submission from PreventionGenetics classifies it as likely benign for OBSCN-related disorder. The global deletion allele frequency of approximately 0.36% (gnomAD exomes) places it above the typical threshold for high-penetrance dominant cardiomyopathy genes. This variant likely has incomplete penetrance, or operates as a low-effect risk allele requiring additional genetic or environmental co-factors. Bi-allelic (homozygous) carriers are essentially absent in population databases, consistent with severe disease or embryonic lethality; heterozygous carrier status is the clinically relevant state.

Practical Implications

Given the conflicting ClinVar evidence and the emerging-to-moderate population data on OBSCN truncating variants as a class, rs71180793 heterozygous carriers warrant a measured response: not alarm, but not dismissal. Cardiac echocardiography can rule out subclinical cardiomyopathy; an ECG or Holter monitor can assess for arrhythmia burden. Decisions about intensity of follow-up should factor in personal and family history of cardiomyopathy, arrhythmia, or unexplained syncope. Carriers who participate in high-intensity competitive sport may wish to discuss pre-participation cardiac screening with a sports cardiologist.

Interactions

OBSCN truncating variants may compound with pathogenic variants in other sarcomere genes — particularly titin (TTN) and desmoplakin (DSP)⁸⁸ titin (TTN) and desmoplakin (DSP)
Both identified alongside OBSCN mutations in DCM explant cohorts — to produce more severe phenotypes. OBSCN's titin-binding domain positions it in the same structural circuit as TTN, and co-occurrence of truncating variants in both genes may produce additive haploinsufficiency beyond what either alone causes. No formal compound action data exist for rs71180793 specifically, but clinicians evaluating OBSCN carriers for cardiomyopathy risk should consider comprehensive sarcomere gene panel testing.

The APOL1 gene encodes apolipoprotein L1¹¹ apolipoprotein L1
APOL1 is a serum protein that kills trypanosomes — the parasites causing African sleeping sickness — by forming pores in their membranes, a critical component of the innate immune defense against Trypanosoma brucei²² Trypanosoma brucei
The single-celled parasite transmitted by tsetse flies that causes African sleeping sickness, fatal if untreated. The rs73885319 variant (c.1024A>G) produces a serine-to-glycine change at position 342, located in the SRA-interacting domain³³ SRA-interacting domain
The serum resistance-associated (SRA) domain is where the trypanosome protein binds to neutralize APOL1; G1 variants alter this binding site. This variant is one half of the G1 risk haplotype — the other being rs60910145 (p.Ile384Met) — which are in near-complete linkage disequilibrium and almost always inherited together.

The Mechanism

APOL1 normally circulates in trypanosome lytic factor (TLF)⁴⁴ trypanosome lytic factor (TLF)
HDL-like particles in human blood that kill non-human-infective trypanosomes by forming ion channels in parasite membranes complexes and kills trypanosomes by inserting into their endosomal membranes and forming cation-selective pores. The human-infective subspecies T.b. rhodesiense evolved a serum resistance-associated (SRA) protein⁵⁵ serum resistance-associated (SRA) protein
A virulence factor that binds APOL1's SRA-interacting domain, neutralizing its trypanolytic activity and enabling the parasite to survive in human blood that binds and neutralizes wild-type APOL1. The G1 variant (S342G + I384M) alters the SRA-binding site so the parasite can no longer neutralize APOL1, restoring trypanolytic activity against T.b. rhodesiense.

The kidney disease mechanism involves the same pore-forming function turned against host cells. In podocytes — the specialized kidney cells that maintain the glomerular filtration barrier⁶⁶ glomerular filtration barrier
The three-layer filter in the kidney that allows waste to pass into urine while retaining proteins and blood cells — G1-variant APOL1 causes excessive cation flux, cell swelling, and ultimately podocyte injury and death⁷⁷ podocyte injury and death
G1/G2 APOL1 expressed in cell culture causes potassium efflux, sodium influx, cell swelling, and cytotoxicity at rates far exceeding wild-type APOL1. This damage is recessive: one copy of G1 is tolerated because sufficient wild-type APOL1 maintains normal podocyte function, but two risk alleles (G1/G1, G1/G2, or G2/G2) overwhelm the protective capacity.

The Evidence

The landmark 2010 discovery⁸⁸ landmark 2010 discovery
Genovese et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329:841-845 identified APOL1 G1 and G2 as the causal variants behind the excess kidney disease burden in African Americans, with odds ratios of 10.5 (95% CI: 6.0-18.4) for focal segmental glomerulosclerosis (FSGS) and 7.3 (95% CI: 5.6-9.5) for hypertension-attributed end-stage kidney disease in those carrying two risk alleles. Subsequent studies expanded the associations: OR 29 for HIV-associated nephropathy (HIVAN)⁹⁹ OR 29 for HIV-associated nephropathy (HIVAN)
Kopp et al. JASN 2011 — APOL1 genetic variants in FSGS and HIV-associated nephropathy, OR 5.4 for lupus collapsing glomerulopathy, and a hazard ratio of 1.88¹⁰¹⁰ hazard ratio of 1.88
Parsa et al. NEJM 2013 — APOL1 risk variants, race, and progression of CKD; HR 1.88 (95% CI 1.2-2.9) for composite renal endpoint for CKD progression in the AASK and CRIC cohorts.

The risk is strongly recessive¹¹¹¹ strongly recessive
Approximately 10-15% of African Americans carry two APOL1 risk alleles (G1/G1, G1/G2, or G2/G2), conferring substantially elevated kidney disease risk; one copy confers trypanosome resistance without kidney risk. Heterozygous carriers have the evolutionary advantage — trypanosome resistance — without the kidney cost, a classic example of balancing selection¹²¹² balancing selection
Similar to sickle cell trait: heterozygous carriers are protected against malaria, while homozygotes develop sickle cell disease comparable to sickle cell and malaria.

The G1 risk allele frequency is approximately 23% in African Americans and up to 40% in West African populations (Yoruba), but is essentially absent (<0.01%) in European, East Asian, and South Asian populations. This means APOL1-associated kidney disease is almost exclusively a condition of African-ancestry populations — a critical factor in the 3-4 fold higher rate of end-stage kidney disease among African Americans compared to European Americans.

Practical Implications

The clinical impact depends entirely on how many risk alleles you carry. One copy of the G1 variant (AG genotype) provides the trypanosome resistance benefit with no measurable kidney risk — this is the evolutionary "sweet spot." Two risk alleles (GG, or compound heterozygous with G2) create substantial kidney disease susceptibility, though penetrance is incomplete: most two-risk-allele carriers never develop kidney disease, suggesting additional triggers (infections like HIV, inflammatory conditions, or other genetic modifiers) are required.

For carriers of two risk alleles, the most important actions are kidney function monitoring via regular estimated GFR and urine albumin-to-creatinine ratio (UACR) testing, aggressive blood pressure management to protect glomerular function, and avoiding nephrotoxic agents when possible. The N264K protective modifier¹³¹³ N264K protective modifier
Gupta et al. Nat Commun 2023 — APOL1 p.N264K variant on a G2 haplotype reduces FSGS risk by nearly 100% (rs2239785) can ameliorate G2-associated risk, though it does not modify G1 risk.

Interactions

The G1 risk haplotype requires BOTH rs73885319 (S342G) and rs60910145 (I384M) — these two missense variants are in near-complete linkage disequilibrium and together define the G1 allele. APOL1 kidney risk follows a recessive model where any combination of two risk alleles is pathogenic: G1/G1 homozygosity, G1/G2 compound heterozygosity (with rs71785313, the G2 6-bp deletion), or G2/G2 homozygosity all confer similar risk. A compound action covering the G1+G2 interaction (rs73885319 + rs71785313) should be created when both variants are in the database, as the combined genotype assessment is critical for risk stratification.

The N264K modifier variant (rs2239785) is co-inherited exclusively with the G2 allele and reduces G2-associated FSGS risk by approximately 100%, effectively converting a G2 haplotype to behave like G0 (wild-type). This modifier does not affect G1-associated risk. HIV infection, lupus, and other inflammatory conditions act as "second hits" that dramatically increase penetrance in two-risk-allele carriers.

Every vein in your body is held in shape by a scaffold of collagen fibres woven through the vessel wall. Collagen type XXVII — encoded by COL27A1 — is one of the structural proteins in this scaffold. It is a fibrillar collagen first characterised in cartilage, where it organises the pericellular matrix around chondrocytes and guides the transition from cartilage to bone. The same structural role extends to connective tissue elsewhere, including the walls of veins and the sheaths surrounding tendons.

This intronic variant in COL27A1 sits at position 114,283,167 on chromosome 9 (GRCh38). Although it falls within an intron and does not change the amino acid sequence, intronic variants can influence splicing efficiency, transcript abundance, or regulatory element function — all of which alter how much functional collagen a tissue produces.

The Mechanism

COL27A1 encodes the alpha-1 chain of a minor fibrillar collagen. Its triple-helical domain forms long non-banded fibrous structures and thin banded fibrils that contribute tensile strength to the pericellular matrix¹¹ pericellular matrix
the immediate extracellular scaffold surrounding each cell. In venous walls, collagen fibres resist the hydrostatic pressure of blood, maintaining lumen diameter and keeping valve leaflets correctly positioned. When collagen quality or quantity is reduced — whether by a rare pathogenic variant or by a common regulatory variant like rs753085 — the vein wall becomes more compliant, predisposing to dilation, valve incompetence, and eventually varicose veins.

The A allele at rs753085 likely alters COL27A1 splicing or expression through an intronic regulatory element. The precise molecular mechanism has not been characterised for this specific variant, but the GWAS signal at this locus (among 49 signals identified across 46 susceptibility loci in the largest varicose veins study to date) places it firmly within the extracellular matrix pathway that controls venous wall stiffness.

The Evidence

The primary evidence comes from a genome-wide association study of 810,625 individuals²² genome-wide association study of 810,625 individuals
Ahmed et al. Genome-wide association analysis and replication in 810,625 individuals with varicose veins. Nature Communications, 2022 — 135,514 varicose vein cases and 675,111 controls drawn from UK Biobank and 23andMe. The study identified 49 association signals at 46 loci, with biological pathway enrichment in extracellular matrix biology, (lymph)angiogenesis, vascular smooth muscle cell migration, and apoptosis. The COL27A1 locus on chromosome 9 emerged as one of these novel susceptibility signals.

Supporting the connective tissue role of this gene, Saunders et al. (2013)³³ Saunders et al. (2013)
Investigation of variants within the COL27A1 and TNC genes and Achilles tendinopathy in two populations. J Orthop Res, 2013 studied rs753085 alongside three other COL27A1 variants in Achilles tendinopathy cohorts from South Africa and Australia. While no single variant reached individual significance, the broader genomic region containing COL27A1 and tenascin-C showed a significant haplotype association with tendinopathy, reinforcing that COL27A1 variants collectively influence connective tissue integrity across different anatomical sites.

The evidence is categorised as moderate: the GWAS finding is well-powered and biologically coherent, but the specific causal variant and functional mechanism at this locus have not yet been resolved.

Practical Actions

For individuals carrying one or two copies of the A allele, the actionable implications centre on protecting venous wall integrity through factors that support collagen synthesis and reduce venous pressure loading. Vitamin C is the required cofactor for prolyl hydroxylase, the enzyme that cross-links collagen triple helices; without adequate vitamin C, newly synthesised collagen is structurally deficient. Compression stockings directly counteract the venous hypertension that drives varicose vein progression by reducing transmural pressure on the vein wall. Weight management reduces the hydrostatic load on lower-limb veins, and prolonged static standing or sitting — a documented risk factor for varicose veins — should be interrupted with movement.

For carriers with a personal or family history of varicose veins, or who are in occupations involving prolonged standing, earlier consideration of venous ultrasound assessment is appropriate.

Interactions

COL27A1 shares functional overlap with other structural collagen genes including COL3A1 (vascular Ehlers-Danlos syndrome) and COL1A1/COL1A2 (osteogenesis imperfecta, connective tissue laxity). Variants in matrix metalloproteinases (MMP1, MMP3, MMP9) that degrade collagen may compound the effect of reduced COL27A1 expression by accelerating collagen turnover in vein walls. Tenascin-C (TNC), whose gene neighbours COL27A1 on chromosome 9q32, participates in the same extracellular matrix scaffold; combined variation across both genes was shown to influence tendinopathy risk.

The endocannabinoid system is one of the most pervasive modulatory systems in the human brain. At its center sits CB1¹¹ CB1
Cannabinoid receptor type 1 — a G-protein-coupled receptor that, when activated, inhibits neurotransmitter release at presynaptic terminals across the cortex, hippocampus, amygdala, basal ganglia, and cerebellum, encoded by the CNR1 gene on chromosome 6. CB1 is the most abundant G-protein-coupled receptor in the central nervous system, serving as the primary target for the body's own endocannabinoid ligands — anandamide and 2-arachidonoylglycerol (2-AG) — and the same receptor that THC from cannabis activates. How much CB1 is expressed, and where, shapes how powerfully drugs and reward-related experiences activate the brain's reinforcement circuits.

The rs806368 variant sits in the 3' untranslated region (3'UTR)²² 3' untranslated region (3'UTR)
The non-coding region at the end of a gene's mRNA that contains regulatory sequences controlling how much protein is produced, how stable the mRNA is, and where in the cell it is translated of CNR1. Rather than changing the CB1 receptor protein itself, this variant alters gene regulation — specifically, it controls the production of a novel CNR1 transcript that is expressed throughout the brain's reward and emotional processing circuits.

The Mechanism

Rs806368 functions as an eQTL³³ eQTL
Expression quantitative trait locus — a genetic variant that explains variation in the level of mRNA expression for a nearby gene. eQTLs are a key class of functional variants linking GWAS associations to biological mechanisms for a previously unknown CNR1 transcript variant. A landmark brain expression study⁴⁴ brain expression study
Tao R et al. Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia. Transl Psychiatry, 2020 identified rs806368 as the top eQTL for this novel transcript across three brain regions: the dorsolateral prefrontal cortex⁵⁵ dorsolateral prefrontal cortex
DLPFC — a region critical for executive function, impulse control, and working memory (p = 8.42E-06), hippocampus (p = 4.46E-08), and caudate nucleus (p = 7.29E-08). The novel transcript contains an alternative 5' exon that is 48 nucleotides longer than the canonical form and harbors approximately 40 transcription factor binding sites — including three STAT protein binding sites not present in the standard transcript. The minor C allele, paradoxically the risk allele in substance dependence research, is associated with lower expression of this novel transcript, suggesting that reduced CB1 receptor levels in key brain circuits may heighten vulnerability to substance reinforcement.

The Evidence

Substance dependence vulnerability. The first comprehensive study of rs806368 in addiction was by Zuo et al. 2007⁶⁶ Zuo et al. 2007
Zuo L et al. CNR1 variation modulates risk for drug and alcohol dependence. Biol Psychiatry, 2007 in 1,001 European and African American individuals. Rs806368 (labeled SNP8) showed the highest linkage disequilibrium signals, and interaction between rs806368 and a second CNR1 variant (rs6454674/SNP3) produced p-values of 0.0002 for drug dependence alone and 0.007 for alcohol dependence — the two variants together exerted stronger genetic effects than either did alone.

Cannabis dependence. An analysis of 1,923 European-American individuals from 219 families by Agrawal et al. 2009⁷⁷ Agrawal et al. 2009
Agrawal A et al. Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence. Am J Med Genet B, 2009 found rs806368 significantly associated with cannabis dependence (p = 0.05, Z = 1.92), with the minor allele frequency of 0.20 in Europeans. The TT genotype was the most common in cases.

Cannabis-related brain structure. The rs806368-rs1049353 haplotype was found to moderate the relationship between cannabis exposure and brain structure: in a longitudinal study⁸⁸ a longitudinal study
Hill SY et al. Lifetime use of cannabis from longitudinal assessments, cannabinoid receptor (CNR1) variation, and reduced volume of the right anterior cingulate. Psychiatry Res Neuroimaging, 2016, heavy cannabis users carrying the at-risk haplotype showed a 17.6% volume reduction in the right anterior cingulate cortex⁹⁹ 17.6% volume reduction in the right anterior cingulate cortex
The anterior cingulate cortex integrates emotion, attention, and executive control. It is a hub for detecting cognitive conflicts and motivating goal-directed behavior compared to non-users — substantially greater than users without the haplotype.

Alcohol dependence. A study of 298 male alcoholics by Marcos et al. 2012¹⁰¹⁰ Marcos et al. 2012
Marcos M et al. Cannabinoid receptor 1 gene is associated with alcohol dependence. Alcohol Clin Exp Res, 2012 found that the TGC haplotype (involving the rs806368 C allele) was significantly overrepresented in alcohol-dependent individuals (p = 0.004), and a gene-gene interaction between the G allele of rs6454674 and the C allele of rs806368 reached p = 0.009. While this appears to assign risk to the C allele in an haplotype context, the independent rs806368-T/T genotype remained the highest-risk genotype in the broader substance dependence literature.

Nicotine dependence. Rs806368 participates in a female-specific nicotine dependence haplotype: Chen et al. 2008¹¹¹¹ Chen et al. 2008
Chen X et al. Cannabinoid receptor 1 gene association with nicotine dependence. Arch Gen Psychiatry, 2008 identified haplotype rs2023239-rs12720071-rs806368(C) as significantly associated with nicotine dependence and Fagerström Test scores in two independent samples (p < 0.001 and p = 0.009), with effects restricted to women.

Impulsivity. Rs806368 was significantly associated with impulsivity (p < 0.0006) in a study of Southwest California Mission Indians by Ehlers et al. 2007¹²¹² Ehlers et al. 2007
Ehlers CL et al. Association between single nucleotide polymorphisms in the cannabinoid receptor gene (CNR1) and impulsivity in southwest California Indians. Twin Res Hum Genet, 2007, where it was one of four CNR1 SNPs associated with impulsive personality traits — a risk factor for addiction vulnerability.

Practical Implications

Knowing your rs806368 genotype provides important context for cannabis use decisions. The TT genotype, which predominates in people of European and African ancestry (~62% globally), carries the highest documented risk for developing cannabis use disorder and experiencing cannabis-related brain structural changes with heavy use. The endocannabinoid system is particularly sensitive to external cannabinoids (THC) early in life, when CB1 receptor expression is highest and neural circuits are still developing. Adolescent and young-adult cannabis exposure carries substantially greater risk for dependence and brain structural changes in TT carriers.

For TT carriers, the specific substance avoidance implications are also broader: the same CB1 regulatory variation that increases cannabis vulnerability has been documented in alcohol, nicotine, and cocaine dependence contexts — a signal that the endocannabinoid reward circuit plays a general role in addiction susceptibility.

Understanding this genetic context does not change what cannabis does pharmacologically, but it does meaningfully shift the probability calculus. CB1 receptor expression shapes how powerfully THC signals are transduced in reward circuitry — lower baseline expression of the novel CNR1 transcript may amplify the relative impact of exogenous cannabinoids.

Interactions

Rs806368 forms a tight haplotype block with rs1049353 (the other well-studied CNR1 3'UTR variant; D' = 0.95), and research frequently analyzes these together. A second CNR1 variant, rs6454674, interacts with rs806368 at the gene-gene level to produce synergistic effects on substance dependence risk greater than either alone. Rs2023239, another CNR1 intronic variant, participates in haplotypes that predict cannabis craving, hippocampal volume changes, and nicotine dependence. Separately, the FAAH gene (rs324420 C385A) — which controls the breakdown of anandamide — has been shown to interact with CNR1 markers in modulating affective responses to THC and alcohol-related sleep quality, with compound effects observed in cannabis cue reactivity studies.

Bilirubin is best known as the yellow pigment of jaundice — a signal that something is wrong with the liver. But in small amounts, unconjugated bilirubin is a normal and potent endogenous antioxidant, and the enzyme responsible for clearing it from the blood, UGT1A1 (UDP-glucuronosyltransferase 1A1)¹¹ UGT1A1 (UDP-glucuronosyltransferase 1A1)
a Phase II liver enzyme that conjugates bilirubin with glucuronic acid for biliary excretion, varies substantially across people. The variant rs887829 — designated UGT1A1*80 — sits in the promoter region of UGT1A1, approximately 211 base pairs upstream of the TATA box TA-repeat sequence. It is in near-complete linkage disequilibrium (r² ≈ 0.99) with UGT1A1*28²² UGT1A1*28
the (TA)7TAA insertion in the TATA box that directly reduces UGT1A1 transcription by ~70%, meaning rs887829 reliably tags the *28 haplotype in most populations and serves as a practical proxy in clinical pharmacogenomics testing.

The Mechanism

The T allele at rs887829 marks the *28 haplotype, which carries seven TA repeats in the promoter TATA box rather than the usual six. The extra repeat reduces UGT1A1 binding efficiency for transcriptional machinery, lowering enzyme production and slowing bilirubin conjugation in the liver. Heterozygous CT carriers have intermediate UGT1A1 activity; TT homozygotes typically have bilirubin levels roughly 65% higher than CC homozygotes and fall within the Gilbert syndrome phenotype spectrum — mildly elevated unconjugated (indirect) bilirubin, especially during fasting or illness.

This same enzyme handles the glucuronidation of multiple drugs. Atazanavir, an HIV protease inhibitor, directly inhibits UGT1A1, compounding the effect in TT carriers and causing pronounced jaundice. Irinotecan, a chemotherapy drug, is converted to its active metabolite SN-38, which is subsequently inactivated by UGT1A1 glucuronidation — TT carriers accumulate SN-38, increasing risk of severe neutropenia and diarrhea.

The Evidence

Bilirubin and cardiovascular risk — observational vs. causal:

The Framingham Heart Study (n=1,780, 24-year follow-up)³³ Framingham Heart Study (n=1,780, 24-year follow-up)
Lin et al., Circulation 2006 reported that *28 TT homozygotes had hazard ratios of 0.36 for CVD and 0.30 for coronary heart disease compared with carriers of the *1 allele — an apparently striking ~65% protection. Multiple smaller studies reinforced this picture.

However, a landmark UK Biobank analysis (n=463,060 genotyped for rs887829)⁴⁴ UK Biobank analysis (n=463,060 genotyped for rs887829)
Gill et al., BMJ Medicine 2023 using Mendelian randomization found that while observational bilirubin-cardiovascular associations are real and consistent, the genetic instrument showed no causal effect of bilirubin on cardiovascular disease outcomes. The authors concluded that bilirubin likely acts as a biomarker of underlying health rather than as an active cardiovascular protective molecule, and that it represents a poor target for therapeutic intervention. Only 3% of rs887829 TT homozygotes in the UK Biobank had a recorded clinical diagnosis of Gilbert syndrome, illustrating how undercoded the condition is.

Endothelial function:

A controlled study of 108 Gilbert syndrome patients vs matched controls⁵⁵ 108 Gilbert syndrome patients vs matched controls
Vítek et al., Metabolism 2012 found improved flow-mediated vasodilation (7.2% vs 5.9%) and lower oxidative stress markers in those with hyperbilirubinemia, confirming a biological signal — but whether this is cause or correlation cannot be established from the data alone.

Drug safety — the actionable findings:

For atazanavir, CPIC guidelines based on rs887829 genotype show positive predictive values for bilirubin-related drug discontinuation within 96 weeks of 60% in Europeans, 29% in Hispanics, and 20% in Black patients — strongly supporting pre-treatment genotyping. For irinotecan, decreased UGT1A1 activity in TT carriers leads to SN-38 accumulation with increased risk of grade 3-4 neutropenia and diarrhea; dose adjustment or closer monitoring is clinically justified.

Practical Actions

The clearest actionable implications of rs887829 are pharmacogenomic. Anyone considering atazanavir as HIV treatment or irinotecan-based chemotherapy should have their UGT1A1 genotype factored into treatment decisions. For TT homozygotes starting atazanavir, clinicians should advise on the high probability of visible jaundice and consider alternative antiretrovirals unless the patient accepts this risk. For irinotecan, starting at a reduced dose (typically one step down) and monitoring closely for myelosuppression is the evidence-based approach for TT carriers.

The cardiovascular story is biologically interesting but not currently actionable: the Mendelian randomization evidence does not support targeting bilirubin levels for cardiovascular risk modification.

Interactions

rs887829 is in near-complete LD (r² ≈ 0.99) with the UGT1A1*28 TA-repeat variant (rs8175347/rs3064744) — these variants track together in most populations. The related rs4148323 (*6, Gly71Arg) is a second independent UGT1A1 loss-of-function allele common in East Asian populations; compound heterozygotes carrying both *28 and *6 (common in East Asian populations) have substantially greater UGT1A1 impairment than either allele alone and face amplified drug toxicity risk with irinotecan. The interaction between rs887829 (as a *28 tag) and rs4148323 (*6) is a candidate compound action for East Asian patients on irinotecan-based chemotherapy.

Ghrelin is the body's primary hunger hormone — a gut-derived peptide that rises before meals, falls after eating, and drives appetite through the growth hormone secretagogue receptor (GHSR-1a)¹¹ growth hormone secretagogue receptor (GHSR-1a)
The only known peripherally-derived orexigenic receptor; signals through both hypothalamic homeostatic circuits and mesolimbic reward pathways. The amount of GHSR protein expressed in appetite-regulating brain regions determines how powerfully ghrelin can drive eating behavior. rs9819506 sits approximately 5 kb upstream of rs490683 in the GHSR promoter haplotype block²² GHSR promoter haplotype block
A cluster of SNPs in the 5′-regulatory region of GHSR that tend to be inherited together; variants in this block collectively influence GHSR transcription levels. It has been associated with body weight and weight loss response in two independent cohorts, though the mechanistic basis appears to lie in linkage disequilibrium with nearby functional variants rather than in a direct promoter effect of its own.

The Mechanism

Unlike rs490683 — the characterized functional SNP in the same region, where the G allele preserves a nuclear factor 1 (NF-1) transcription factor binding site and elevates GHSR expression — rs9819506 has not been found to alter protein binding in gel-shift (EMSA) experiments³³ gel-shift (EMSA) experiments
Electrophoretic mobility shift assay: a technique that detects whether specific nuclear proteins bind to a DNA sequence by observing a "shift" in band migration on a gel. The Mager 2008 analysis found no differential binding between the C and T alleles of rs9819506, despite the clear association with body weight. This pattern — phenotypic association without local functional evidence — is characteristic of a tag SNP: rs9819506 likely tracks a nearby functional variant through LD rather than disrupting a regulatory element itself. Its position in the same promoter haplotype block as the NF-1 site variant rs490683 supports this interpretation. Individuals carrying the C allele (the more common allele globally, ~68%) tend toward higher GHSR expression-associated phenotypes; T allele carriers track toward lower ghrelin signaling capacity.

The Evidence

The foundational study from Mager et al. 2008⁴⁴ Mager et al. 2008
PLoS One; Finnish Diabetes Prevention Study cohort; N=507 overweight adults with impaired glucose tolerance followed 3 years during an intensive lifestyle intervention genotyped 7 GHSR SNPs and found rs9819506 associated with body weight at 3-year follow-up (p=0.036). Individuals homozygous for the A allele (coding-strand notation; equivalent to plus-strand TT) showed the lowest body weight across the study period, with a direct pairwise comparison between GG and AA genotypes reaching p=0.030. Importantly, this was a weight-tracking association rather than a weight-loss-response finding — rs490683, not rs9819506, showed the clearest dietary intervention response in that dataset.

The Matzko et al. 2012 RYGB cohort⁵⁵ Matzko et al. 2012 RYGB cohort
Geisinger Health System; N>650 patients undergoing Roux-en-Y gastric bypass; genotyped for rs9819506 and rs490683; 30-month post-surgical weight loss trajectories found that rs9819506 was independently associated with post-surgical weight loss in an additive model (p<0.0001). The minor T allele was associated with more weight loss; CC homozygotes lost slightly less weight over 30 months. The effect was also significant under a dominant model for T allele carriage (p=0.0072). This replicated the directionality of the Mager 2008 finding: T allele = lower body weight / better weight loss response. A 2023 systematic review⁶⁶ 2023 systematic review
Duarte et al., Current Obesity Reports; reviewed SNPs associated with body weight trajectory after bariatric surgery confirmed rs9819506 among variants predictive of higher post-surgical weight loss.

Practical Actions

CC homozygotes (the most common genotype at ~42% globally) carry the allele associated with higher baseline body weight and slightly attenuated weight loss responses across both lifestyle and surgical interventions. The mechanism is likely indirect — through LD with GHSR promoter variants that maintain elevated ghrelin receptor expression — meaning that ghrelin's appetite drive may be somewhat stronger at baseline. Dietary strategies that target ghrelin suppression (particularly high-protein meals, which produce the strongest acute ghrelin suppression of all macronutrients) are the most genotype-relevant lever available. CT heterozygotes carry one T allele and occupy an intermediate position. TT individuals show the most favourable association with weight outcomes.

Interactions

rs9819506 sits in the same GHSR promoter haplotype block as rs490683 (already on the platform) and rs2922126. Because rs9819506 is likely a tag SNP rather than a functional variant, individuals carrying both rs9819506-CC and rs490683-GG may experience compounding ghrelin receptor expression effects — though the degree of independent contribution from rs9819506 beyond what rs490683 already captures depends on the LD structure between the two. rs696217 (GHRL Leu72Met) affects postprandial ghrelin ligand suppression; combined disruption of both the ligand level (rs696217) and receptor signaling (this locus and rs490683) could produce additive appetite dysregulation.

RAD51B¹¹ RAD51B
RAD51 paralog B, a member of the RAD51 family of proteins essential for repairing DNA double-strand breaks through homologous recombination is best known as a genome guardian — a protein that physically handles the most dangerous type of DNA damage a cell can experience. rs1885013 is an intronic variant within RAD51B on chromosome 14q24.1, sitting within a locus that genome-wide association studies have now linked to both asthma susceptibility and rheumatoid arthritis risk. The same DNA repair gene influencing two seemingly unrelated inflammatory diseases points to a shared biological thread: the role of genomic stability in immune cell function.

The Mechanism

RAD51B is one of five RAD51 paralogs (alongside RAD51C, RAD51D, XRCC2, XRCC3) that form the Rad51B-Rad51C-Rad51D-XRCC2 complex²² Rad51B-Rad51C-Rad51D-XRCC2 complex
This four-protein complex is required for homologous recombination repair of DNA double-strand breaks and is particularly active in S-phase cells undergoing replication stress. rs1885013 falls within an intron and has no direct effect on protein sequence. Instead, it is a proxy for regulatory variation at this locus — either tagging an as-yet-uncharacterized regulatory element affecting RAD51B expression in immune cell subsets, or marking a causal variant in linkage disequilibrium.

The connection between RAD51B and immune function is supported by mechanistic data. Lymphocytes in rheumatoid arthritis patients show elevated RAD51B mRNA expression relative to healthy controls³³ elevated RAD51B mRNA expression relative to healthy controls
Galita et al. 2024 detected significantly elevated RAD51B gene expression in peripheral blood mononuclear cells from RA patients, and RA patients carrying risk variants in RAD51B demonstrate impaired repair of DNA double-strand breaks in lymphocytes — with an OR of 73.4 for deficient repair in those carrying risk haplotypes. Activated immune cells — including T and B lymphocytes undergoing clonal expansion during an allergic or autoimmune response — produce high levels of reactive oxygen species that damage DNA. When RAD51B-dependent repair is subtly altered, these cells may accumulate genomic instability, potentially prolonging activation or altering differentiation decisions in ways that amplify allergic and inflammatory responses.

The opposing risk directions at this locus for asthma (G allele risk) versus rheumatoid arthritis (A allele risk) are consistent with the well-documented genetic trade-off between atopic/type-2 inflammatory diseases and autoimmune/type-1 diseases at several shared immune loci. This immunological seesaw⁴⁴ immunological seesaw
The inverse relationship between atopic disease susceptibility and autoimmune disease susceptibility at the same loci reflects opposite polarization of immune responses — type 2 (atopic) vs type 1 (autoimmune) — at shared genetic control points is a recurrent finding in large GWAS studies.

The Evidence

The asthma association was established in a large GWAS by Ferreira et al. AJHG 2019⁵⁵ Ferreira et al. AJHG 2019
Genetic Architectures of Childhood- and Adult-Onset Asthma Are Partly Distinct; UK Biobank n=447,628; validation in 23andMe n=262,767. rs1885013 achieved genome-wide significance for both childhood-onset asthma (OR 1.085, p=3×10⁻²⁵) and adult-onset asthma (OR 1.056, p=3×10⁻¹³), placing it among the robustly replicated asthma loci. Each copy of the G allele increases asthma susceptibility additively.

The rheumatoid arthritis association at this locus was initially identified by McAllister et al. Arthritis Rheum 2013⁶⁶ McAllister et al. Arthritis Rheum 2013
meta-GWAS of 17,581 RA cases and 20,160 controls; proxy SNP rs911263 in RAD51B p=4×10⁻⁸, OR 0.89, and confirmed in the Ishigaki et al. Nature Genetics 2022⁷⁷ Ishigaki et al. Nature Genetics 2022
multi-ancestry GWAS of 276,020 samples from five ancestral groups; 124 loci including RAD51B mega-analysis. Mechanistic studies by Galita et al. 2024⁸⁸ Galita et al. 2024
45 RA patients vs 45 healthy controls; bleomycin comet assay of DNA double-strand break repair efficiency demonstrated that RA patients with RAD51B risk variants show dramatically impaired DNA damage repair in lymphocytes, with OR 73.4 for deficient repair in RAD51B risk haplotype carriers. Zhi et al. Sci Rep 2017⁹⁹ Zhi et al. Sci Rep 2017
965 RA cases, 2,511 controls; Han Chinese population confirmed the association using the proxy SNP rs911263 (OR 0.64 for the protective allele, p=4.8×10⁻⁵) and additionally found the protective allele associated with reduced joint erosion severity.

Evidence level is classified as moderate: the asthma and RA GWAS associations are robustly replicated and genome-wide significant, but the functional mechanism (which specific regulatory element drives the effect and in which immune cell type) has not yet been characterized for rs1885013 itself.

Practical Actions

For GG homozygotes — who carry two copies of the G risk allele (~10% of Europeans, ~1% of East Asians) — the asthma susceptibility signal is strongest. The actionable focus is monitoring for early asthma symptoms and reducing known triggers that stress airway epithelium. Given that RAD51B is also a cancer susceptibility gene (breast, pancreatic), GG carriers with a family history of these cancers should ensure they receive standard cancer screening.

For AG heterozygotes — present in about 41% of Europeans — asthma risk is modestly elevated. Standard allergen management and awareness of asthma symptoms remain appropriate.

For AA homozygotes — the most common genotype (~50% of Europeans) — asthma risk through this locus is not elevated. However, the A allele is associated with modest RA susceptibility, and those with a personal or family history of RA should ensure they meet standard clinical monitoring thresholds.

Interactions

RAD51B does not act alone in DNA repair. It forms an obligate complex with RAD51C (encoded by PALB2 partner), and both are part of the broader homologous recombination network. Functional overlap exists with RAD51 itself (rs7180135, rs1801321) and other paralogs (XRCC2, XRCC3, RAD51D). In RA patients, combinatorial analysis shows that co-carrying risk variants at multiple DNA repair loci (RAD51B + RAD51 + NBS1) further amplifies the risk of deficient lymphocyte repair.

The opposing-direction association pattern at rs1885013 (G allele protective for RA, A allele protective for asthma) raises the possibility of compound effects in individuals carrying risk alleles at both this locus and independent RA or atopic loci. Cross-category compound actions should be considered between this SNP and pathway partners in the autoimmune-tolerance and allergy-atopic categories if a user carries GG at this locus plus RA-specific risk alleles elsewhere.